Jeffrey P. Ward

Jeffrey P. Ward

Auto-generated profile, based on publicly available information

Jeffrey P. Ward

Department of Medicine/Division of Oncology, Washington University School of Medicine, St. Louis, MO, United States

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2014 in Nature
Verified
Journal Article
Open access
PDF file
MGMatthew M. Gubin
Matthew M. Gubin
XZXiuli Zhang
Xiuli Zhang
HSHeiko Schuster
Heiko Schuster
ECEtienne Caron
Etienne Caron
JWJeffrey P. Ward
Jeffrey P. Ward
RSRobert D. Schreiber
Robert D. Schreiber
A carcinogen-induced mouse tumour model is used here to show that mutant tumour-specific antigens are targets for CD8+ T-cell responses, mediating tumour regression after checkpoint blockade immunotherapy, and that these antigens can be used effectively in therapeutic vaccines; this advance potentially opens the door to personalized cancer vaccines. In many individuals, immunosuppression is mediated by T-lymphocyte associated antigen-4 (CTLA-4) and programmed death-1 (PD-1), immunomodulatory receptors expressed on T cells. Matthew Gubin et al. use the MCA mouse sarcoma model to show that mutant tumour antigens serve as targets for CD8+ T-cell responses, mediating tumour regression after checkpoint blockade immunotherapy with anti-PD-1 and/or anti-CTLA-4. The authors demonstrate that these antigens can be used effectively in therapeutic vaccines, suggesting a possible route to personalized cancer vaccines. The immune system influences the fate of developing cancers by not only functioning as a tumour promoter that facilitates cellular transformation, promotes tumour growth and sculpts tumour cell immunogenicity1,2,3,4,5,6, but also as an extrinsic tumour suppressor that either destroys developing tumours or restrains their expansion1,2,7. Yet, clinically apparent cancers still arise in immunocompetent individuals in part as a consequence of cancer-induced immunosuppression. In many individuals, immunosuppression is mediated by cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and programmed death-1 (PD-1), two immunomodulatory receptors expressed on T cells8,9. Monoclonal-antibody-based therapies targeting CTLA-4 and/or PD-1 (checkpoint blockade) have yielded significant clinical benefits—including durable responses—to patients with different malignancies10,11,12,13. However, little is known about the identity of the tumour antigens that function as the targets of T cells activated by checkpoint blockade immunotherapy and whether these antigens can be used to generate vaccines that are highly tumour-specific. Here we use genomics and bioinformatics approaches to identify tumour-specific mutant proteins as a major class of T-cell rejection antigens following anti-PD-1 and/or anti-CTLA-4 therapy of mice bearing progressively growing sarcomas, and we show that therapeutic synthetic long-peptide vaccines incorporating these mutant epitopes induce tumour rejection comparably to checkpoint blockade immunotherapy. Although mutant tumour-antigen-specific T cells are present in progressively growing tumours, they are reactivated following treatment with anti-PD-1 and/or anti-CTLA-4 and display some overlapping but mostly treatment-specific transcriptional profiles, rendering them capable of mediating tumour rejection. These results reveal that tumour-specific mutant antigens are not only important targets of checkpoint blockade therapy, but they can also be used to develop personalized cancer-specific vaccines and to probe the mechanistic underpinnings of different checkpoint blockade treatments.

23 October 2019 in Nature
Verified
Journal Article
Closed access
PDF file
EAElise Alspach
Elise Alspach
DLDanielle M. Lussier
Danielle M. Lussier
AMAlexander P. Miceli
Alexander P. Miceli
IKIlya Kizhvatov
Ilya Kizhvatov
MDMichel DuPage
Michel DuPage
RSRobert D. Schreiber
Robert D. Schreiber

12 August 2020 in Nature
Verified
Journal Article
Closed access
PDF file
SFStephen T. Ferris
Stephen T. Ferris
VDVivek Durai
Vivek Durai
RWRenee Wu
Renee Wu
DTDerek J. Theisen
Derek J. Theisen
JWJeffrey P. Ward
Jeffrey P. Ward
KMKenneth M. Murphy
Kenneth M. Murphy

1 October 2020 in Cell
Verified
Journal Article
Closed access
DWDaniel K Wells
Daniel K Wells
MBMarit M van Buuren
Marit M van Buuren
KDKristen K Dang
Kristen K Dang
VHVanessa M Hubbard-Lucey
Vanessa M Hubbard-Lucey
KSKathleen C F Sheehan
Kathleen C F Sheehan
NDNadine A Defranoux
Nadine A Defranoux

31 January 2017 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
TNTakuro Noguchi
Takuro Noguchi
JWJeffrey P. Ward
Jeffrey P. Ward
MGMatthew M. Gubin
Matthew M. Gubin
CACora D. Arthur
Cora D. Arthur
SLSang Hun Lee
Sang Hun Lee
RSRobert D. Schreiber
Robert D. Schreiber
Antibody blockade of programmed death-1 (PD-1) or its ligand, PD-L1, has led to unprecedented therapeutic responses in certain tumor-bearing individuals, but PD-L1 expression's prognostic value in stratifying cancer patients for such treatment remains unclear. Reports conflict on the significance of correlations between PD-L1 on tumor cells and positive clinical outcomes to PD-1/PD-L1 blockade. We investigated this issue using genomically related, clonal subsets from the same methylcholanthrene-induced sarcoma: a highly immunogenic subset that is spontaneously eliminated in vivo by adaptive immunity and a less immunogenic subset that forms tumors in immunocompetent mice, but is sensitive to PD-1/PD-L1 blockade therapy. Using CRISPR/Cas9-induced loss-of-function approaches and overexpression gain-of-function techniques, we confirmed that PD-L1 on tumor cells is key to promoting tumor escape. In addition, the capacity of PD-L1 to suppress antitumor responses was inversely proportional to tumor cell antigenicity. PD-L1 expression on host cells, particularly tumor-associated macrophages (TAM), was also important for tumor immune escape. We demonstrated that induction of PD-L1 on tumor cells was IFNγ-dependent and transient, but PD-L1 induction on TAMs was of greater magnitude, only partially IFNγ dependent, and was stable over time. Thus, PD-L1 expression on either tumor cells or host immune cells could lead to tumor escape from immune control, indicating that total PD-L1 expression in the immediate tumor microenvironment may represent a more accurate biomarker for predicting response to PD-1/PD-L1 blockade therapy, compared with monitoring PD-L1 expression on tumor cells alone. Cancer Immunol Res; 5(2); 106–17. ©2017 AACR.

1 January 2016
Verified
Book Chapter
Closed access
JWJeffrey P. Ward
Jeffrey P. Ward
MGMatthew M. Gubin
Matthew M. Gubin
RSRobert D. Schreiber
Robert D. Schreiber